The company ends research for a cancer treatment and plans to cut 40% of employees.
http://www.minyanville.com/sectors/biotech-pharma/articles/Geron-Drops-as-Drug-Failure-Marks/12/4/2012/id/46348
http://www.minyanville.com/sectors/biotech-pharma/articles/Geron-Drops-as-Drug-Failure-Marks/12/4/2012/id/46348
No comments:
Post a Comment